FATE NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Fate Therapeutics Inc · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 2.41 USD
-13.3% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 41.5% above the Trend Line and sits at 64.7% of its 52-week range. The latest completed week returned -13.3%, after a 14.8% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 61/100 conviction, while the latest news-sentiment score is 54/100. Near-term considerations: volume confirmation is below normal; earnings are due in 13d.

Setup score 60 out of 100
Latest Close 2.41 USD 24 Jul 2026
1W Return -13.3% latest completed week
4W Return 14.8% short-term follow-through
12W Return 57.5% quarterly tape
Trend Breadth 51.9% 27 of 52 weeks active
Volume Ratio 0.3x vs 13-week average
What is working
  • The trend backdrop is active with a 13-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Activity pressure is positive on the latest completed week.
  • Activity pressure is constructive, supporting the smart-money activity read.
What could go wrong
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • The share remains more than 20% below its 52-week high.
  • The latest week was a sharp negative move.
  • Recent volatility is running well above the one-year baseline.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -13.3% Latest completed week; four-week move 14.8%. Indicator stack 74/71 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 61/100 conviction; expected move 35.3%. News sentiment 54/100 54 relevant articles in the latest sentiment read. Event risk 13d Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 41.5% above the Trend Line and sits at 64.7% of its 52-week range. The latest completed week returned -13.3%, after a 14.8% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.3x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.9712-week average 0.77

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.97Current proprietary activity-pressure read.
Buy signals2Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 14.8% over four weeks, 57.5% over 12 weeks, and 94.4% over one year. The current trend has remained active for 13 consecutive weeks.

Performance by holding period

1W-13.3%
4W14.8%
12W57.5%
26W99.2%
52W94.4%
Active trend streak13 weeks
Active weeks in one year27
Trend breadth51.9%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.07Latest activity-pressure read.
Pressure change26.3%Four-week change in activity pressure.
Leadership54.34Latest relative-leadership reading.
RS change38.9%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 82% Model confidence 78%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength23/100Blend of value, momentum, and quality. Underlying universe rank 78; rank 1 is best.
Value28/100Relative valuation strength. Underlying universe rank 73; rank 1 is best.
Quality2/100Profitability and accounting quality. Underlying universe rank 99; rank 1 is best.
Momentum93/100Medium-term price momentum. Underlying universe rank 8; rank 1 is best.
Growth12/100Revenue and earnings growth. Underlying universe rank 89; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
44.5x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-30.8%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-415.8%
Gross profit retained from each unit of revenue.
Operating margin
-2056.8%
Operating profit retained from revenue.
Free-cash-flow margin
-1553.2%
Free cash flow generated from revenue.
Return on invested capital
-44.9%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-52.6%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-0.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

FATE shows volatility options pressure with a 61/100 conviction score, put-call volume ratio of 0.15, expected move of 35.3%, and Sharemaestro trend signal active.

Conviction61/100
Expected move35.3%
Put/call volume0.15
Pressure83
Speculation21
Volatility96
Trend agreement45
Open options detail
Insider activity16 / 4

16 acquisitions and 4 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment54/100

Weighted news tone is neutral across 54 relevant articles.

18 positive · 29 neutral · 7 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
Options expected move35.3%Nearest-chain priced movement where available.
52-week drawdown-25.4%Distance below the 52-week high.
13-week volatility24.2%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher16 of 2610 weeks finished lower.
Best week+56.2%Week of 8 May.
Worst week-30.3%Week of 5 Jun.
Latest week-13.3%Week of 24 Jul.

Shape of recent returns

Strong gains12
Modest gains4
Flat weeks0
Modest losses1
Sharp losses9
Recent vol24.2%13-week weekly-return volatility.
Base vol15.9%52-week weekly-return volatility.
Up/down split28/24Count of positive and negative weeks in the 52-week window.
Average skew13.2% / -10.1%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape58/100

Trend, activity pressure, participation, and risk combine to a 58/100 tape read.

 Indicator analysis91/100

Latest 12-week confirmation: trend 12/12, activity pressure 12/12, relative leadership 12/12.

Activity pressure 0.97; No reversal markers Factors33/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 57; Small Cap Core rank 77 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options51/100

FATE shows volatility options pressure with a 61/100 conviction score, put-call volume ratio of 0.15, expected move of 35.3%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 35.3% Sentiment54/100

Weighted news tone is neutral across 54 relevant articles.

Irenic Capital Management LP Purchases Shares of 878,055 Fate Therapeutics, Inc. $FATE Insiders16 / 4

16 acquisitions and 4 disposals in the latest 180-day insider tape.

 Earnings13d

Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 20262.41 USD-13.3%1.70 USD2.48 USD1.0754.346.8MOn
17 Jul 20262.78 USD-10.3%1.66 USD2.49 USD1.2577.1716.7MOn
10 Jul 20263.10 USD6.2%1.60 USD2.50 USD1.1492.5917.3MOn
3 Jul 20262.92 USD39.0%1.53 USD2.51 USD0.9688.2724.2MOn
26 Jun 20262.10 USD0.5%1.47 USD2.52 USD0.8439.1239.4MOn
19 Jun 20262.09 USD1.5%1.44 USD2.54 USD1.0633.5110.5MOn
12 Jun 20262.06 USD4.0%1.41 USD2.56 USD1.3435.7911.8MOn
5 Jun 20261.98 USD-30.3%1.37 USD2.58 USD1.5334.0625.4MOn
29 May 20262.84 USD26.2%1.34 USD2.60 USD1.7683.2524.8MOn
22 May 20262.25 USD28.2%1.29 USD2.62 USD1.6151.4822.1MOn
15 May 20261.75 USD-26.6%1.27 USD2.63 USD1.2220.5416.8MOn
8 May 20262.39 USD56.2%1.26 USD2.66 USD1.0764.2632.5MOn
1 May 20261.53 USD15.0%1.23 USD2.67 USD0.6012.238.9MOn
24 Apr 20261.33 USD-4.3%1.22 USD2.70 USD0.30-1.335.2MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.